Exome Asset Management’s Maze Therapeutics MAZE Stock Holding History

Exome Asset Management’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.64M	Buy	+88,510	New	+$3.91M	1.37%	33

Other funds holding MAZE

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Exome Asset Management's MAZE Position: Q1 2026 in Review

Exome Asset Management opened a new position in Maze Therapeutics (MAZE) in Q1 2026: 88,510 shares worth $2.64M. The stake represents 1.37% of the portfolio and ranks #33 among its holdings.

165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

Exome Asset Management held 88,510 shares of Maze Therapeutics worth $2.64M as of Q1 2026.
Maze Therapeutics was a new Exome Asset Management position in Q1 2026.
Maze Therapeutics made up 1.37% of Exome Asset Management's portfolio in Q1 2026, its #33 holding.
165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.